Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum IBEX Technologies Inc V.IBT

IBEX Technologies Inc., through its wholly owned subsidiary, IBEX Pharmaceuticals Inc., manufactures and markets enzymes for biomedical use. IBEX Pharmaceutical Inc.’s primary business is the manufacture and selling of high purity enzymes for in-vitro diagnostics and research. The Company also makes and sell osteoarthritis kits (ELISA’s) for pre-clinical research. The Company has developed a... see more

TSXV:IBT - Post Discussion

IBEX Technologies Inc > Signs Definitive Agreement for Sale of the Company V.IBT
View:
Post by Betteryear2 on Feb 12, 2024 8:25am

Signs Definitive Agreement for Sale of the Company V.IBT

MONTREAL, Feb. 12, 2024 (GLOBE NEWSWIRE) -- IBEX Technologies Inc. (“IBEX” or the “Company”) (TSX Venture: IBT) is pleased to announce that it has entered into a binding acquisition agreement dated February 9, 2024 (the “Acquisition Agreement”) and related agreements with 15720273 Canada Inc. (the “Purchaser”), a newly-incorporated, wholly-owned subsidiary of BBI Solutions OEM Limited (“BBI”), whereby BBI will acquire all of the issued and outstanding shares of IBEX at a price of $1.45 per share in cash. The transaction will be effected by way of an amalgamation of IBEX and the Purchaser under the Canada Business Corporations Act (the “Amalgamation”) to form an amalgamated corporation (“Amalco”). Under the Amalgamation, each issued and outstanding common share of IBEX will be exchanged for one redeemable preferred share of Amalco, which will immediately be redeemed for $1.45 cash per share. The total consideration is approximately $37.9 million.

IBEX Technologies Signs Definitive Agreement for Sale of (globenewswire.com)
Comment by winnerswing on Apr 08, 2024 3:11pm
Why an HALT today? Higher bid?
Comment by winnerswing on Apr 09, 2024 1:55am
okay I think they halted to let brokers to pick up all the shares.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities